PharmaNet and Phase Forward sign EDC deal

By Gareth Macdonald

- Last updated on GMT

Related tags: Phase forward, Clinical trial, Pharmaceutical industry

PharmaNet will offer Phase Forward’s InForm EDC and trial management platform to customers under a new deal announced today.

InForm, an electronic data capture (EDC) platform designed to streamline the clinical trials process, is widely used in the industry by both drugmakers such as GlaxoSmithKline (GSK), AstraZeneca and Novartis, and contract research organisations (CRO) like Quintiles and Parexel.

More recently the system won the US Society for Clinical Data Management’s (SCDM) award for data driven innovation after Phase Forward's work with Merck & Co on a direct data loading (DDL) project.

This broad industry acceptance coupled with previous collaborations in clinical research, were key motivations for the new multi-year deal as PharmaNet’s president of late-stage development Thomas Newman explained.

"We chose to team with Phase Forward on the basis of our successful collaboration on behalf of several pharmaceutical companies.

"That experience indicated the complementary nature of Phase Forward`s established leadership in EDC technology solutions and our expertise in providing clinical trial services to a broad range of industries.”

Steve Powell, Phase forward’s senior VP, echoed these thoughts, suggesting that: “Our InForm EDC solution is a perfect addition to PharmaNet`s expertise and we look forward to building on and expanding our work together​."

Preclinical partnership with Azopharma

Collaboration has been an important part of PharmaNet’s strategy in recent weeks, starting with its accord with Azopharma.

That partnership, announced on October 15, saw PharmaNet and Azopharma team up on a business development plan to co-promote their respective strengths in early-stage drug development and clinical research.

At the time PharmaNet CEO Jeffrey McMullen said that the offerings are a good fit, explaining that the deal is an important boost for his firm in the preclinical toxicology and bioanalytics.

Azopharma CEO Phil Meeks was also upbeat about the collaboration, suggesting that: “Both companies will be introduced to new sets of clients and the clients will be exposed to new compelling solutions for their early phase development.​”

Related news

Show more

Related products

show more

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

What to consider when working with CRFs

What to consider when working with CRFs

Formedix | 21-Sep-2020 | Technical / White Paper

For a study to be successful, data collected must be correct and complete. To be correct and complete, forms must be well planned with meticulous attention...

Lessons Learned: Clinical Trials During a Pandemic

Lessons Learned: Clinical Trials During a Pandemic

PCM TRIALS | 01-Sep-2020 | Technical / White Paper

In a recent survey of clinical trial professionals (including pharmaceutical sponsors, CROs, site representatives and vendors), respondents reported that...

Covance Touchless Drug and Device Vigilance Vision

Covance Touchless Drug and Device Vigilance Vision

Covance Patient Safety | 01-Sep-2020 | Data Sheet

Automation tools enable organizations to identify patterns in structured and unstructured data and facilitate automation of the entire product vigilance...

Related suppliers

Follow us


View more